DXR

Peers: UTMD HAE LMAT CVRX CTSO NUWE ELMD HSCS IRMD BJDX

Index	-
Market Cap	49.17M
Enterprise Value	43.38M
Income	6.23M
Sales	0.15M
Book/sh	8.88
Cash/sh	0.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Jan 05, 2018
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	-
IPO	Jul 25, 1983

P/E	6.89
Forward P/E	-
PEG	-
P/S	327.82
P/B	0.95
P/C	8.49
P/FCF	-
EV/EBITDA	6.96
EV/Sales	289.22
Quick Ratio	245.27
Current Ratio	245.27
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	1.22
EPS next Y	-0.03
EPS next Q	-0.04
EPS this Y	-320.00%
EPS next Y	85.71%
EPS next 5Y	-
EPS past 3/5Y	13.20% -
Sales past 3/5Y	- -
EPS Y/Y TTM	234.88%
Sales Y/Y TTM	-85.48%
EPS Q/Q	-791.41%
Sales Q/Q	-93.80%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	49.20%
Insider Trans	0.00%
Inst Own	7.96%
Inst Trans	-0.02%
ROA	14.20%
ROE	14.24%
ROIC	12.02%
Gross Margin	-106.52%
Oper. Margin	4024.05%
Profit Margin	4021.89%
SMA20	-9.46%
SMA50	-18.02%
SMA200	-21.67%
Trades

Shs Outstand	5.84M
Shs Float	2.97M
Short Float	0.11%
Short Ratio	0.15
Short Interest	0.00M
52W High	14.76 -42.95%
52W Low	8.40 0.24%
Volatility	4.45% 4.07%
ATR (14)	0.44
RSI (14)	28.90
Beta	0.46
Rel Volume	0.30
Avg Volume	21.98K
Volume	5,843

Perf Week	-6.44%
Perf Month	-19.12%
Perf Quarter	-17.77%
Perf Half Y	-16.22%
Perf YTD	-42.92%
Perf Year	-35.03%
Perf 3Y	5.71%
Perf 5Y	-23.94%
Perf 10Y	6.90%
Recom	1.00
Target Price	20.00
Prev Close	8.45
Price	8.42
Change %	-0.36%

Consensus

Strong Buy

Avg. Price Target

$20.00

Implied Upside

+137.5%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 16, 2019	Initiated	AAscendiant Capital Markets	Buy	$20	+137.5%

Oct-15-26 08:00AM	Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 (GlobeNewswire)
Oct-14-26 08:00AM	Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 (GlobeNewswire)
Oct-13-26 08:00AM	Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 (GlobeNewswire)
Oct-01-26 08:00AM	Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 (GlobeNewswire)
Sep-08-26 05:40PM	Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire)
08:00AM	Loading…
Sep-01-26 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter (GlobeNewswire) +8.14%
Jul-29-26 10:40PM	Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas (GlobeNewswire)
Jul-07-26 08:00AM	Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas (GlobeNewswire)
Jun-02-26 08:00AM	Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor (GlobeNewswire)
Apr-28-26 08:00AM	Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis (GlobeNewswire) +5.39%
Apr-08-26 08:00AM	Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center (GlobeNewswire)
Mar-26-26 08:00AM	Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 (GlobeNewswire)
Mar-17-26 08:00AM	Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions (GlobeNewswire)
Mar-10-26 08:00AM	Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress (GlobeNewswire)
Mar-09-26 08:00AM	Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 (GlobeNewswire)
08:30AM	Loading…
Mar-03-26 08:30AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
08:00AM	Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share (GlobeNewswire)
Feb-24-26 08:00AM	Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee (GlobeNewswire)
Feb-10-26 08:00AM	Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business (GlobeNewswire)
Jan-23-26 08:00AM	Daxor Corporation Announces $9 Million Registered Direct Offering (GlobeNewswire) -8.13%
Nov-25-25 08:00AM	Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer (GlobeNewswire)
Oct-21-25 08:00AM	Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit (GlobeNewswire)
Oct-15-25 08:00AM	Daxor's New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 (GlobeNewswire)
Sep-30-25 08:00AM	Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA (GlobeNewswire) +6.21%
Sep-23-25 08:00AM	Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting (GlobeNewswire)
Sep-04-25 08:00AM	Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care (GlobeNewswire) +6.59%
Sep-03-25 08:00AM	Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter (GlobeNewswire) -5.27%
Aug-12-25 08:00AM	Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available (GlobeNewswire) +12.78%
Aug-07-25 07:55AM	Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System (GlobeNewswire) +5.00%
08:00AM	Loading…
Jul-22-25 08:00AM	Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions (GlobeNewswire)
May-14-25 08:00AM	Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal (GlobeNewswire)
May-13-25 08:00AM	Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems (GlobeNewswire)
May-07-25 08:00AM	Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology (GlobeNewswire)
May-06-25 08:00AM	Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance (GlobeNewswire)
Apr-22-25 08:00AM	Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Apr-17-25 08:00AM	Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 (GlobeNewswire)
Apr-15-25 08:00AM	New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival (GlobeNewswire) -5.83%
Apr-10-25 08:00AM	Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer (GlobeNewswire)
Apr-02-25 08:00AM	Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo (GlobeNewswire)
Mar-28-25 08:00AM	Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks (GlobeNewswire)
Mar-04-25 04:55PM	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 (GlobeNewswire)
03:53PM	Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 (GlobeNewswire)
09:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Feb-28-25 08:00AM	Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center (GlobeNewswire)
Feb-27-25 08:00AM	Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals (GlobeNewswire)
Feb-19-25 08:00AM	Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 (GlobeNewswire)
Feb-18-25 08:00AM	Daxor to Exhibit at World's Largest Critical Care Conference (GlobeNewswire)
Feb-14-25 08:00AM	Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment (GlobeNewswire)
Feb-13-25 08:00AM	New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care (GlobeNewswire)
Dec-18-24 08:00AM	Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum (GlobeNewswire)
Oct-09-24 08:00AM	DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 (GlobeNewswire)
Oct-08-24 08:00AM	Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 05:00PM	Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device (GlobeNewswire)
Sep-19-24 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 (GlobeNewswire)
Sep-12-24 08:00AM	Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management (GlobeNewswire)
Sep-05-24 08:00AM	Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee (GlobeNewswire)
Sep-04-24 08:30AM	Leading Central Florida Hospital Implements Daxor's BVA-100 Blood Volume Diagnostic for Heart Failure Patient Care (GlobeNewswire) +5.40%
Sep-03-24 04:05PM	Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter (GlobeNewswire)
12:15PM	Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 08:00AM	Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network (GlobeNewswire) +21.25%
Aug-06-24 08:00AM	Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Aug-05-24 08:00AM	Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide (GlobeNewswire) +11.96%
Jul-24-24 08:00AM	Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jul-11-24 08:00AM	Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide (GlobeNewswire)
Jun-18-24 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting (GlobeNewswire)
Jun-05-24 08:00AM	Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-16-24 08:00AM	New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion (GlobeNewswire)
Apr-15-24 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 ) (GlobeNewswire)
Apr-10-24 08:00AM	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital (GlobeNewswire)
Apr-01-24 08:00AM	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 (GlobeNewswire)
Mar-28-24 10:38AM	Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 08:00AM	Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics (GlobeNewswire) +6.74%
Mar-22-24 08:00AM	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 (GlobeNewswire)
Mar-18-24 02:18PM	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 (GlobeNewswire)
02:18PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-11-24 08:00AM	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base (GlobeNewswire)
Mar-08-24 08:00AM	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients (GlobeNewswire)
Feb-26-24 08:00AM	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-12-24 08:00AM	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions (GlobeNewswire)
Feb-07-24 08:00AM	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts (GlobeNewswire)
Jan-29-24 08:00AM	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting (GlobeNewswire)
Jan-16-24 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress (GlobeNewswire)
Jan-09-24 08:00AM	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES (GlobeNewswire)
Jan-02-24 08:30AM	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer (GlobeNewswire)
Nov-13-23 08:00AM	New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients (GlobeNewswire) +7.05%
Nov-09-23 08:00AM	Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume (GlobeNewswire)
Oct-13-23 08:00AM	Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-11-23 08:00AM	New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 08:00AM	Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program (GlobeNewswire)
Sep-27-23 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023 (GlobeNewswire)
Sep-26-23 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
Sep-11-23 12:00PM	Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients (GlobeNewswire)
Sep-07-23 09:15AM	Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 04:15PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
04:05PM	Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023 (GlobeNewswire)
Aug-10-23 08:00AM	JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100® (GlobeNewswire)
Jul-12-23 08:00AM	JACC-HF Study Compares Daxors BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients (GlobeNewswire)
Jul-11-23 08:00AM	Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S. (GlobeNewswire)
Jul-05-23 08:00AM	Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feldschuh Michael Richard	Chief Executive Officer	Apr 08 '26	Buy	9.07	1,000	9,070	213,694	Apr 10 01:54 PM
Michel Robert J	Chief Financial Officer	Mar 31 '26	Buy	9.90	1,000	9,900	21,050	Mar 31 06:28 PM

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

ChairmanMr. Michael Richard Feldschuh

M.B.A.Mr. Robert J. Michel CPA

Chief Scientific Officer & DirectorMr. Jonathan Adam Feldschuh

M.B.A.Dr. John Lynn Jefferies FACC

Vice President of Development & OperationsMs. Linda Cooper

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Daxor Corp

Upgrade your Finviz experience